Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Charlot Biosciences
AddedFeb 18, 2024
UpdatedJun 18, 2026
Charlot Biosciences

Charlot Biosciences

Pre-Seed

CBio: Innovating diagnostic test kits with microfluidics and machine vision for pathogen detection.

HQ
Tampa, FL, US
Founded
2016
Overview
Compare
Fundraising
Employees
Website

Charlot Biosciences (CBio) was founded with the mission to innovate diagnostic test kits using advanced microfluidics and machine vision technologies. The company focuses on developing analytical equipment to ensure the efficacy of cell and viral vector gene therapies. Their flagship platform, cellPhoresis®, leverages novel separation science techniques, machine vision, and edge computing to identify hidden differences in cell populations, enhancing the accuracy and reliability of pathogen detection.

Notable figures affiliated with CBio include experts in biotechnology and diagnostics, although specific names are not provided. The company has secured investments from key players in the biotech industry, contributing to its rapid development and deployment of cutting-edge diagnostic solutions. CBio's achievements include successful pilot studies identifying neural stem and progenitor cell subpopulations, demonstrating the platform's potential to revolutionize diagnostic testing and improve patient care outcomes.

Charlot Biosciences - Similar Companies

BioFluidica logo

BioFluidica

biofluidica.com

BioCeryx logo

BioCeryx

CytoMag logo

CytoMag

LumaCyte logo

LumaCyte

lumacyte.com

Character Biosciences logo

Character Biosciences

characterbio.com

RareCyte logo

RareCyte

rarecyte.com

CellChorus logo

CellChorus

cellchorus.com

Capio Biosciences logo

Capio Biosciences

Probius logo

Probius

probius.bio

Correlia Biosystems logo

Correlia Biosystems

CNine Biosolutions logo

CNine Biosolutions

PathoGene logo

PathoGene

Droplet Biosciences logo

Droplet Biosciences

dropletbiosci.com

Circulogene Theranostics logo

Circulogene Theranostics

circulogene.com

Cellarity logo

Cellarity

Charlot Biosciences - Quick Facts

Who are Charlot Biosciences' competitors?

Companies similar to Charlot Biosciences include BioFluidica, BioCeryx, CytoMag and LumaCyte.

When was Charlot Biosciences founded?

Charlot Biosciences was founded in 2016.

Where is Charlot Biosciences' headquarters located?

Charlot Biosciences' headquarters is located in Tampa, FL, US.

When was Charlot Biosciences' last funding round?

Charlot Biosciences' most recent funding round was for $760k (USD) in September 2019.

How much has Charlot Biosciences raised to-date?

As of Sep 15, 2019, Charlot Biosciences has raised a total of $760k (USD).

How many employees does Charlot Biosciences have?

Charlot Biosciences has 5 employees as of Feb 4, 2024.

Charlot Biosciences - Classification

Industry
  • Hardware
Ownership
  • Venture Capital
Technology
  • Analytics
  • Machine Learning
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
  • Government
Main Product
  • Diagnostic Kits
Tags
  • Biotech
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software